Artelo Biosciences Inc
ARTL7.195USD
-0.060-0.85%
Close 06/13, 16:00（ET）Quotes delayed by 15 min
23.61MMarket Cap
LossP/E TTM
More Details of Artelo Biosciences Inc Company
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.
Company Info
Ticker SymbolARTL
Company nameArtelo Biosciences Inc
IPO dateOct 13, 2015
Founded at2011
CEOMr. Gregory D. (Greg) Gorgas
Number of employees6
Security typeOrdinary Share
Fiscal year-endOct 13
Address505 Lomas Santa Fe, Suite 160
CitySOLANA BEACH
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code92075
Phone18589257049
Websitehttps://artelobio.com/
Ticker SymbolARTL
IPO dateOct 13, 2015
Founded at2011
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Gregory D. (Greg) Gorgas
Mr. Gregory D. (Greg) Gorgas
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
3.41K
--
Ms. Connie L. Matsui
Ms. Connie L. Matsui
Independent Chairperson of the Board
Independent Chairperson of the Board
630.00
--
Mr. Steven (Steve) Kelly
Mr. Steven (Steve) Kelly
Independent Director
Independent Director
139.00
--
Ms. Tamara A. (Seymour) Favorito, CPA
Ms. Tamara A. (Seymour) Favorito, CPA
Independent Director
Independent Director
--
--
Dr. Gregory R. Reyes, M.D., Ph.D.
Dr. Gregory R. Reyes, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Douglas Blayney, M.D.
Dr. Douglas Blayney, M.D.
Independent Director
Independent Director
--
--
Dr. R. Martin Emanuele, Ph.D.
Dr. R. Martin Emanuele, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Gregory D. (Greg) Gorgas
Mr. Gregory D. (Greg) Gorgas
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
3.41K
--
Ms. Connie L. Matsui
Ms. Connie L. Matsui
Independent Chairperson of the Board
Independent Chairperson of the Board
630.00
--
Mr. Steven (Steve) Kelly
Mr. Steven (Steve) Kelly
Independent Director
Independent Director
139.00
--
Ms. Tamara A. (Seymour) Favorito, CPA
Ms. Tamara A. (Seymour) Favorito, CPA
Independent Director
Independent Director
--
--
Dr. Gregory R. Reyes, M.D., Ph.D.
Dr. Gregory R. Reyes, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Douglas Blayney, M.D.
Dr. Douglas Blayney, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Geode Capital Management, L.L.C.
0.82%
Citadel Advisors LLC
0.69%
Gorgas (Gregory D)
0.62%
Susquehanna International Group, LLP
0.62%
UBS Financial Services, Inc.
0.39%
Other
96.86%
Shareholders
Shareholders
Proportion
Geode Capital Management, L.L.C.
0.82%
Citadel Advisors LLC
0.69%
Gorgas (Gregory D)
0.62%
Susquehanna International Group, LLP
0.62%
UBS Financial Services, Inc.
0.39%
Other
96.86%
Shareholder Types
Shareholders
Proportion
Investment Advisor
1.01%
Investment Advisor/Hedge Fund
0.90%
Individual Investor
0.81%
Hedge Fund
0.81%
Other
96.46%
Institutional Shareholding
Updated: Mon, Mar 3
Updated: Mon, Mar 3
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
23
63.92K
1.95%
-37.27K
2024Q4
25
63.92K
1.95%
-99.86K
2024Q3
26
51.99K
1.61%
-115.04K
2024Q2
32
55.13K
1.71%
-137.29K
2024Q1
31
54.26K
1.68%
-150.15K
2023Q4
38
55.07K
1.83%
-168.01K
2023Q3
40
80.20K
2.79%
-263.28K
2023Q2
40
67.48K
2.36%
-288.11K
2023Q1
40
75.80K
2.65%
-285.67K
2022Q4
41
142.96K
5.02%
-236.79K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Geode Capital Management, L.L.C.
17.35K
0.53%
--
--
Dec 31, 2024
Gorgas (Gregory D)
20.45K
0.62%
--
--
Feb 27, 2025
UBS Financial Services, Inc.
13.30K
0.41%
+13.30K
--
Dec 31, 2024
Tower Research Capital LLC
3.82K
0.12%
-1.36K
-26.34%
Dec 31, 2024
Matsui (Connie L)
3.78K
0.12%
--
--
Feb 27, 2025
Northern Trust Investments, Inc.
2.68K
0.08%
+2.68K
--
Dec 31, 2023
Blayney (Douglas W)
834.00
0.03%
--
--
Feb 27, 2025
Kelly (Steven)
834.00
0.03%
--
--
Feb 27, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 09, 2022
Merger
15<1
Aug 09, 2022
Merger
15<1
Aug 09, 2022
Merger
15<1
Aug 09, 2022
Merger
15<1
Date
Type
Ratio
Aug 09, 2022
Merger
15<1
Aug 09, 2022
Merger
15<1
Aug 09, 2022
Merger
15<1
Aug 09, 2022
Merger
15<1
